146 related articles for article (PubMed ID: 31899229)
1. Impact of MRI and Targeted Biopsies on Eligibility and Disease Reclassification in MRI-positive Candidates for Active Surveillance on Systematic Biopsies.
Ploussard G; Beauval JB; Lesourd M; Almeras C; Assoun J; Aziza R; Gautier JR; Loison G; Portalez D; Salin A; Tollon C; Soulié M; Malavaud B; Roumiguié M
Urology; 2020 Mar; 137():126-132. PubMed ID: 31899229
[TBL] [Abstract][Full Text] [Related]
2. Performance of systematic, MRI-targeted biopsies alone or in combination for the prediction of unfavourable disease in MRI-positive low-risk prostate cancer patients eligible for active surveillance.
Ploussard G; Beauval JB; Lesourd M; Almeras C; Assoun J; Aziza R; Gautier JR; Loison G; Portalez D; Salin A; Tollon C; Soulié M; Malavaud B; Roumiguié M
World J Urol; 2020 Mar; 38(3):663-671. PubMed ID: 31197523
[TBL] [Abstract][Full Text] [Related]
3. A multicentric study on accurate grading of prostate cancer with systematic and MRI/US fusion targeted biopsies: comparison with final histopathology after radical prostatectomy.
Diamand R; Oderda M; Al Hajj Obeid W; Albisinni S; Van Velthoven R; Fasolis G; Simone G; Ferriero M; Roche JB; Piechaud T; Pastore A; Carbone A; Fiard G; Descotes JL; Marra G; Gontero P; Altobelli E; Papalia R; Kumar P; Eldred-Evans D; Giacobbe A; Muto G; Lacetera V; Beatrici V; Roumeguere T; Peltier A
World J Urol; 2019 Oct; 37(10):2109-2117. PubMed ID: 30652213
[TBL] [Abstract][Full Text] [Related]
4. Relationship Between Prebiopsy Multiparametric Magnetic Resonance Imaging (MRI), Biopsy Indication, and MRI-ultrasound Fusion-targeted Prostate Biopsy Outcomes.
Meng X; Rosenkrantz AB; Mendhiratta N; Fenstermaker M; Huang R; Wysock JS; Bjurlin MA; Marshall S; Deng FM; Zhou M; Melamed J; Huang WC; Lepor H; Taneja SS
Eur Urol; 2016 Mar; 69(3):512-7. PubMed ID: 26112001
[TBL] [Abstract][Full Text] [Related]
5. Pathological findings at radical prostatectomy of biopsy naïve men diagnosed with MRI targeted biopsy alone without concomitant standard systematic sampling.
Luzzago S; Petralia G; Maresca D; Sabatini I; Cordima G; Brescia A; Verweij F; Garelli G; Mistretta FA; Cioffi A; Pricolo P; Alessi S; Ferro M; Matei DV; Renne G; de Cobelli O; Musi G
Urol Oncol; 2020 Dec; 38(12):929.e11-929.e19. PubMed ID: 32600928
[TBL] [Abstract][Full Text] [Related]
6. Active surveillance eligibility of MRI-positive patients with grade group 2 prostate cancer: a pathological study.
Ploussard G; Beauval JB; Lesourd M; Manceau C; Almeras C; Aziza R; Gautier JR; Loison G; Portalez D; Salin A; Tollon C; Soulié M; Malavaud B; Roumiguié M
World J Urol; 2020 Jul; 38(7):1735-1740. PubMed ID: 31612251
[TBL] [Abstract][Full Text] [Related]
7. Prebiopsy MRI and MRI-ultrasound Fusion-targeted Prostate Biopsy in Men With Previous Negative Biopsies: Impact on Repeat Biopsy Strategies.
Mendhiratta N; Meng X; Rosenkrantz AB; Wysock JS; Fenstermaker M; Huang R; Deng FM; Melamed J; Zhou M; Huang WC; Lepor H; Taneja SS
Urology; 2015 Dec; 86(6):1192-8. PubMed ID: 26335497
[TBL] [Abstract][Full Text] [Related]
8. The role of perilesional and multiparametric resonance imaging-targeted biopsies to reduce the risk of upgrading at radical prostatectomy pathology: A retrospective monocentric study.
Diamand R; Hollans M; Lefebvre Y; Sirtaine N; Limani K; Hawaux E; Abou Zahr R; Mattlet A; Albisinni S; Roumeguère T; Peltier A
Urol Oncol; 2022 May; 40(5):192.e11-192.e17. PubMed ID: 35236622
[TBL] [Abstract][Full Text] [Related]
9. Optimized grade group for reporting prostate cancer grade in systematic and MRI-targeted biopsies.
He Y; Shen Q; Fu W; Wang H; Song G
Prostate; 2022 Aug; 82(11):1125-1132. PubMed ID: 35538399
[TBL] [Abstract][Full Text] [Related]
10. Active Surveillance Magnetic Resonance Imaging Study (ASIST): Results of a Randomized Multicenter Prospective Trial.
Klotz L; Loblaw A; Sugar L; Moussa M; Berman DM; Van der Kwast T; Vesprini D; Milot L; Kebabdjian M; Fleshner N; Ghai S; Chin J; Pond GR; Haider M
Eur Urol; 2019 Feb; 75(2):300-309. PubMed ID: 30017404
[TBL] [Abstract][Full Text] [Related]
11. Further reduction of disqualification rates by additional MRI-targeted biopsy with transperineal saturation biopsy compared with standard 12-core systematic biopsies for the selection of prostate cancer patients for active surveillance.
Radtke JP; Kuru TH; Bonekamp D; Freitag MT; Wolf MB; Alt CD; Hatiboglu G; Boxler S; Pahernik S; Roth W; Roethke MC; Schlemmer HP; Hohenfellner M; Hadaschik BA
Prostate Cancer Prostatic Dis; 2016 Sep; 19(3):283-91. PubMed ID: 27184812
[TBL] [Abstract][Full Text] [Related]
12. The prognostic value of high-grade prostate cancer pattern on MRI-targeted biopsies: predictors for downgrading and importance of concomitant systematic biopsies.
Manceau C; Fromont-Hankard G; Beauval JB; Lesourd M; Almeras C; Bajeot AS; Gautier JR; Soulié M; Loison G; Salin A; Tollon C; Malavaud B; Roumiguié M; Ploussard G
World J Urol; 2021 Sep; 39(9):3315-3321. PubMed ID: 33609168
[TBL] [Abstract][Full Text] [Related]
13. Decreased accuracy of the prostate cancer EAU risk group classification in the era of imaging-guided diagnostic pathway: proposal for a new classification based on MRI-targeted biopsies and early oncologic outcomes after surgery.
Ploussard G; Manceau C; Beauval JB; Lesourd M; Almeras C; Gautier JR; Loison G; Salin A; Soulié M; Tollon C; Malavaud B; Roumiguié M
World J Urol; 2020 Oct; 38(10):2493-2500. PubMed ID: 31838560
[TBL] [Abstract][Full Text] [Related]
14. How Would MRI-targeted Prostate Biopsy Alter Radiation Therapy Approaches in Treating Prostate Cancer?
Dix DB; McDonald AM; Gordetsky JB; Nix JW; Thomas JV; Rais-Bahrami S
Urology; 2018 Dec; 122():139-146. PubMed ID: 30172834
[TBL] [Abstract][Full Text] [Related]
15. Multiparametric ultrasound-targeted biopsy compares favorably to multiparametric MRI-transrectal ultrasound fusion-targeted biopsy on initial biopsy of men at risk for prostate cancer.
Fulgham PF
World J Urol; 2018 May; 36(5):713-718. PubMed ID: 29368230
[TBL] [Abstract][Full Text] [Related]
16. Pathological features of Prostate Imaging Reporting and Data System (PI-RADS) 3 MRI lesions in biopsy and radical prostatectomy specimens.
Rahota RG; Diamand R; Malavaud B; Fiard G; Descotes JL; Peltier A; Beauval JB; Roumeguère T; Roumiguié M; Albisinni S; Ploussard G
BJU Int; 2022 May; 129(5):621-626. PubMed ID: 34358405
[TBL] [Abstract][Full Text] [Related]
17. Risk of adverse pathology at prostatectomy in the era of MRI and targeted biopsies; rethinking active surveillance for intermediate risk prostate cancer patients.
Bloom JB; Daneshvar MA; Lebastchi AH; Ahdoot M; Gold SA; Hale G; Mehralivand S; Sanford T; Valera V; Wood BJ; Choyke PL; Merino MJ; Turkbey B; Parnes HL; Pinto PA
Urol Oncol; 2021 Oct; 39(10):729.e1-729.e6. PubMed ID: 33736975
[TBL] [Abstract][Full Text] [Related]
18. Primary magnetic resonance imaging/ultrasonography fusion-guided biopsy of the prostate.
Maxeiner A; Kittner B; Blobel C; Wiemer L; Hofbauer SL; Fischer T; Asbach P; Haas M; Penzkofer T; Fuller F; Miller K; Cash H
BJU Int; 2018 Aug; 122(2):211-218. PubMed ID: 29569320
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of MSKCC Preprostatectomy nomogram in men who undergo MRI-targeted prostate biopsy prior to radical prostatectomy.
Glaser ZA; Gordetsky JB; Bae S; Nix JW; Porter KK; Rais-Bahrami S
Urol Oncol; 2019 Dec; 37(12):970-975. PubMed ID: 31495569
[TBL] [Abstract][Full Text] [Related]
20. The detection of significant prostate cancer is correlated with the Prostate Imaging Reporting and Data System (PI-RADS) in MRI/transrectal ultrasound fusion biopsy.
Cash H; Maxeiner A; Stephan C; Fischer T; Durmus T; Holzmann J; Asbach P; Haas M; Hinz S; Neymeyer J; Miller K; Günzel K; Kempkensteffen C
World J Urol; 2016 Apr; 34(4):525-32. PubMed ID: 26293117
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
